Clinical Trial Update: Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating sustained-release dalfampridine for transverse myelitis and related conditions has completed, with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Transverse Myelitis
• Myelitis Nos
• Neuromyelitis Optica
• Transverse Myelitis

Drugs mentioned

• Ampyra (4-aminopyridine)

Snippet

Sponsor: Johns Hopkins University | Conditions: Transverse Myelitis, Neuromyelitis Optica | Phase 2 | Status: COMPLETED | Results posted: 2018-04-17